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Abstract 1 
There is much epidemiological evidence suggesting a reduced risk of development of 2 
type 2 diabetes (T2D) in habitual coffee drinkers, however to date there have been few longer-3 
term interventions, directly examining the effects of coffee intake on glucose and lipid 4 
metabolism. Previous studies may be confounded by inter-individual variation in caffeine 5 
metabolism. Specifically, the rs762551 single nucleotide polymorphism (SNP) in the CYP1A2 6 
gene has been demonstrated to influence caffeine metabolism, with carriers of the C allele 7 
considered to be of a “slow” metaboliser phenotype. This study investigated the effects of 8 
regular coffee intake on markers of glucose and lipid metabolism in coffee-naïve individuals, 9 
with novel analysis by rs762551 genotype. Participants were randomised to either a coffee 10 
group (n=19) who consumed 4 cups/day instant coffee for 12 weeks or a control group (n=8) 11 
who remained coffee/caffeine free. Venous blood samples were taken pre- and post-12 
intervention. Primary analysis revealed no significant differences between groups. Analysis of 13 
the coffee group by genotype revealed several differences. Prior to coffee intake, the AC 14 
genotype (“slow” caffeine metabolisers, n=9) displayed higher baseline glucose and non-15 
esterified fatty acids (NEFA) than the AA genotype (“fast” caffeine metabolisers, n=10, 16 
p<0.05). Post-intervention, reduced postprandial glycaemia and reduced NEFA suppression 17 
were observed in the AC genotype, with the opposite result observed in the AA genotype 18 
(p<0.05). These observed differences between genotypes warrant further investigation and 19 
indicate there may be no one-size-fits-all recommendation with regard to coffee drinking and 20 
T2D risk. 21 
22 
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Introduction  23 
Diabetes is a major global health issue, with the World Health Organization (WHO) reporting 24 
the prevalence to be 8.5% of the adult population in 2014 (1). Epidemiological studies suggest 25 
a reduced risk of development of type 2 diabetes (T2D) in habitual coffee drinkers who 26 
consume ≥ 1 cup/day (2–6), however differences in preparation method, coffee type, strength 27 
and serving size may confound results. Despite this, many studies report a dose-dependent 28 
effect on T2D risk with the greatest risk reduction observed at the highest coffee intakes. 29 
Interventional studies, however, have so far provided little corroboratory evidence. Studies 30 
investigating the acute effects of caffeinated coffee on the postprandial glucose response have 31 
frequently demonstrated an increased postprandial glucose excursion following coffee 32 
ingestion (7–9), suggesting a potentially detrimental effect of coffee on glucose metabolism, in 33 
direct contrast to the epidemiology.  34 
Few interventional studies have investigated the longer-term effects of coffee on glucose 35 
metabolism, the majority of which have examined the effects only in habitual coffee 36 
drinkers (10–12).  It could be argued that habitual coffee drinkers are not the most appropriate 37 
population to study as they will already have achieved any potential longer-term benefits of 38 
coffee drinking prior to the intervention. Despite this obvious limitation, to our knowledge, 39 
there has only been one study to date to investigate the longer-term effects of coffee drinking 40 
on glucose metabolism in coffee-naïve individuals.  That study recruited overweight, non-41 
coffee drinkers with impaired fasting glucose (IFG) and observed a reduction in the 42 
postprandial glycaemic response following consumption of five cups/day of instant coffee for 43 
16 weeks (13). It is not known whether a similar result would be observed in healthy individuals. 44 
The rs762551 single nucleotide polymorphism (SNP) in the CYP1A2 gene affects the rate of 45 
caffeine metabolism (14), with carriers of the C allele being classed as “slow” caffeine 46 
metabolisers whereas those who are homozygous for the A allele are considered to be of a 47 
“fast” metaboliser phenotype. Associations between coffee drinking and increased risk of 48 
myocardial infarction (15), hypertension (16,17) and IFG (18) have been observed in individuals 49 
who are carriers of the “slow” C allele but not in those with the “fast” AA genotype. It is likely 50 
that these polymorphisms in the CYP1A2 gene will modulate the effects of coffee on glucose 51 
and lipid metabolism however, to our knowledge, this has not previously been investigated. 52 
The current study investigated the effects of 12 weeks of caffeinated coffee consumption on 53 
glucose and lipid metabolism in healthy coffee-naïve individuals, with secondary analysis by 54 
rs762551 genotype.  55 
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Experimental methods 56 
Participants 57 
Thirty adult males and females, aged over 18 y, were recruited from the staff and student 58 
population of the University of Surrey (UK) and from the local community. Participants were 59 
required to have been weight stable for the previous 3 months, to be taking no prescription 60 
medication other than oral contraceptives and to have no history of heart disease, diabetes, liver 61 
disease or any gastrointestinal or endocrine disorders. Smokers and habitual tea/coffee drinkers 62 
(> 4 servings per week) were excluded. One participant dropped out mid-trial for personal 63 
reasons and two were excluded following genotype analysis. Baseline characteristics for the 64 
remaining 27 participants are presented in Table 1. This study was conducted according to the 65 
guidelines laid down in the Declaration of Helsinki and all procedures involving human 66 
subjects were given a favourable ethical opinion by the University of Surrey Ethics Committee. 67 
Written informed consent was obtained from all participants. The study was registered with the 68 
ISRCTN, trial number ISRCTN42321643 (http://www.controlled-trials.com/) and was carried 69 
out between September 2013 and July 2014. 70 
Coffee pre-trial 71 
Interested potential participants underwent a two day coffee pre-trial, prior to full enrolment 72 
on the study, to ensure they could tolerate the treatment and thus reduce attrition rate. Following 73 
screening, they were given eight individually wrapped coffee portions, containing 2 g instant 74 
coffee (a commercially available, 100% Arabica bean blend), the equivalent of 1 tsp, and asked 75 
to consume four per day over the course of two days. Instant coffee was selected to ensure a 76 
consistent dose of caffeine and other coffee components, as other forms, such as espresso and 77 
filter coffee, result in greater variation in the end product, due to the complexity of the brewing 78 
process (19–21).  Furthermore, instant coffee is the most popular form of coffee in the UK, 79 
accounting for almost 75% of retail sales in 2015 (22). The coffee was dissolved in boiling water 80 
and taken without any additions, such as milk, cream, sugar or sweetener. Those who 81 
completed the pre-trial and wished to take part in the study then underwent a 14 day caffeine 82 
washout period prior to their first study visit. During this time they were instructed to consume 83 
no caffeine-containing food or drinks, such as coffee, tea, energy drinks and chocolate. This 84 
included decaffeinated products as the decaffeination process does not completely remove all 85 
caffeine. Participants also completed a four day food and drink diary, which they returned to 86 
the investigators at their first study visit. 87 
Study Design 88 
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An open-label parallel-arm design was employed, with participants randomized, stratified by 89 
gender, into unequal treatment groups (2:1, coffee: control group). After a 14 day caffeine 90 
washout period, participants attended their baseline study visit. Participants were not advised 91 
which group they had been allocated to until after they had completed their first study visit. 92 
Following this visit, those in the coffee intervention group were provided with a supply of 93 
instant coffee portions and asked to consume four per day for 12 weeks, in the same manner as 94 
in the two day pre-trial. They were required to consume no caffeine-containing food or drinks, 95 
other than the supplied coffee, for the duration of the intervention. Those in the control group 96 
were asked to remain caffeine free for 12 weeks. Following the intervention, participants 97 
returned for their final study visit. An overview of the study timeline is presented in Figure 1. 98 
All participants were visited once or twice at random during the 12 week intervention and asked 99 
to provide saliva samples which were frozen at -20 °C immediately after collection; at the end 100 
of the study, salivary caffeine concentrations were analysed in order to monitor compliance. 101 
Participants in the coffee group were asked to return any unused coffee portions at the end of 102 
the study. These were counted and individual mean daily coffee intakes estimated. 103 
Study day protocol 104 
Participants abstained from vigorous exercise for two days prior to each study visit and 105 
consumed a standardized meal the evening before (macaroni cheese, providing 784 kcal 106 
energy, 31.2 g protein, 35.2 g fat, 80.5 g carbohydrate and 10.1 g dietary fibre) and then fasted 107 
for 12 h overnight. Additionally, those in the coffee group stopped taking the coffee sachets 108 
and were asked to consume no caffeine-containing food or drink for two days prior to their 109 
second study visit to ensure all study investigations were in an identical caffeine-free condition.  110 
Participants arrived for each study visit between 08:00 and 09:00. Blood pressure, bodyweight 111 
and body fat were measured and a buccal swab was taken for subsequent DNA analysis. A 112 
cannula was inserted into an antecubital vein and a fasted blood sample was taken. A liquid 113 
meal tolerance test (LMTT) was then carried out: participants consumed a standard liquid meal 114 
(2 x 200 ml Fortisip (Nutricia, Trowbridge, UK), providing 600 kcal energy, 24 g protein, 23 g 115 
fat and 74 g carbohydrate) and further venous blood samples were taken at 15, 30, 60, 90, and 116 
120 minutes postprandially. 117 
Blood sampling 118 
Blood samples were collected into Vacuette® Z serum clot activator tubes (Greiner Bio-One, 119 
UK) and left to stand at room temperature for 30 min to allow clotting before being transferred 120 
onto ice. Blood samples, for the preparation of plasma, were collected into fluoride oxalate 121 
tubes (Teklab, UK) and put straight onto ice. At the end of the study day all samples were 122 
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centrifuged at 1912 x g, 4 °C for 10 min. Plasma and serum aliquots were taken and frozen at 123 
-20 °C for batch analysis at the end of the study. 124 
Plasma glucose and serum total cholesterol, HDL cholesterol, NEFA and triacylglycerol (TAG) 125 
were measured on an ILab 650 analyser (Instrumentation Laboratory, UK). Inter-assay CVs 126 
were 2%, 4%, 9%, 8% and 9% respectively and intra-assay CVs were ≤ 4%, 9%, 9%, 7% and 127 
8%, respectively. Serum insulin concentrations were measured by radioimmunoassay using a 128 
Human Insulin Specific RIA kit (Millipore, UK).  Inter-assay CVs were 11 % and intra-assay 129 
CVs were ≤ 9%. Serum inflammatory markers, IL-6 and TNF-, were analysed by the Clinical 130 
Immunology Service (University of Birmingham, UK), using a bead-based multiplex assay 131 
(Bio-Plex Precision Pro Human Cytokine Assay kit, Bio-Rad, UK). The plate was analysed on 132 
a Luminex-100 plate reader (Bio-Plex Systems, Bio-Rad Laboratories, California, USA) using 133 
a low 'RP1' (low PMT - photomultiplier tube) target setting. Intra-assay CVs were < 10%. 134 
 135 
Salivary caffeine analysis 136 
A 0.5 ml aliquot was taken from each saliva sample and 0.5 ml ethanol added. Samples were 137 
then microcentrifuged for 10 min at 19071 x g, 4 °C. Caffeine concentration was measured by 138 
reversed-phase high performance liquid chromatography (HPLC), using a Synergi Hydro ODS 139 
(C18) 4.6 x 250 mm column, with 35% methanol in water, run in isocratic mode at 0.75 ml/min; 140 
column temperature was 30 °C, injection volume was 20 µl and run time was 10 min. Caffeine 141 
content was determined by measuring the absorbance at 260 nm and 280 nm. 142 
 143 
Coffee analysis 144 
The coffee was analysed for caffeine, trigonelline and chlorogenic acid (CGA) content by 145 
Sciantec Analytical Services (Selby, UK). The results of this analysis are presented in Table 2. 146 
 147 
DNA extraction and analysis 148 
DNA was extracted from buccal cells into MasterAmp DNA extraction solution (Epicentre 149 
Biotechnologies, US) and frozen at -20 °C until required. The extracted DNA was then 150 
analysed for the rs762551 SNP using a 5’-nuclease allelic discrimination assay (Taqman drug 151 
metabolism genotyping assay SNP ID rs762551, gene CYP1A2, Applied Biosystems, UK). 152 
 153 
Statistics 154 
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As this was the first study to compare glycaemic response by genotype, there was no similar 155 
study to base a power calculation on. Sample size was therefore set at 30 participants, with 10 156 
participants in the control group and 20 participants in the coffee group (target 10 participants 157 
per genotype subgroup). This is in line with standard practice in glycaemic index testing, which 158 
recommends a minimum of 10 participants per test food to ensure sufficient statistical 159 
power (23). A retrospective power calculation was performed, using the Harvard statistical 160 
power calculator for parallel trials (24). Based on change in glucose IAUC in the coffee group, 161 
it found that, for 20 participants (10 per genotype), there was an 80% probability (two-sided 162 
0.05 significance level) that the study would detect a difference in treatment if the true 163 
difference between treatments was 59.3 mmol/L.120min, based on the assumption that the SD 164 
for change in glucose IAUC was 44.71 mmol/L.120min. Statistical analysis was carried out 165 
using IBM SPSS Statistics 21 (Chicago, USA). The Matsuda Index (10,000/√([fasting glucose 166 
x fasting insulin] x [mean glucose x mean insulin during LMTT])) (25) was calculated as a 167 
measure of postprandial insulin sensitivity. Homogeneity of variance was checked using 168 
Mauchly’s Test for Sphericity; any violations of the assumption were corrected with the 169 
Greenhouse-Geisser adjustment. Insulin, Matsuda Index, TAG and TNF- data were not 170 
normally distributed, therefore log transformation was applied and parametric tests carried out 171 
on the log-transformed data. Age, IL-6 and HDL cholesterol data were not normally 172 
distributed, either before or after log transformation, therefore non-parametric tests were 173 
carried out on the original data. All other data (glucose time-points, glucose IAUC, NEFA, 174 
total cholesterol, weight, body fat, BMI, systolic and diastolic blood pressure) were normally 175 
distributed. Statistical significance was taken as p<0.05. Differences between coffee and 176 
control groups (primary analysis) and between AA and AC genotypes (secondary analysis), for 177 
all single measures (fasted blood measures, Matsuda Index and anthropometrics), were 178 
compared by either independent samples t test (glucose, insulin, TAG, NEFA, total cholesterol, 179 
TNF-, Matsuda Index, weight, body fat, BMI, systolic and diastolic blood pressure) or Mann-180 
Whitney U test (age, IL-6 and HDL cholesterol). The same tests were used to compare changes 181 
in these measures between groups over the course of the intervention. Baseline differences 182 
between coffee and control groups for the postprandial time-point data (glucose, insulin, TAG 183 
and NEFA, measured at six time-points over a two hour period) were compared by a repeated 184 
measures (six time-points) full factorial fixed effects (treatment, time) linear model. The effects 185 
of the intervention on the postprandial time-point data were compared using a repeated 186 
measures (six time-points) full factorial fixed effects (treatment, visit, time) linear model. 187 
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Similarly, for the secondary analysis, baseline differences between genotypes for the 188 
postprandial time-point data were compared by a repeated measures (six time-points) full 189 
factorial fixed effects (genotype, time) linear model and the effects of the intervention on the 190 
postprandial time-point data were compared using a repeated measures (six time-points) full 191 
factorial fixed effects (genotype, visit, time) linear model. Gender is a potential confounder to 192 
these results, as differences between men and women in postprandial glucose, insulin, TAG 193 
and NEFA response have been reported (26–28), so these models were also run with gender as an 194 
additional fixed effect. This additional analysis has only been reported where the results differ 195 
from the original model. 196 
 197 
Results 198 
Participant compliance 199 
All participants in the coffee group had at least one random saliva sample with a caffeine 200 
concentration over 3 µM. There were no significant differences between genotypes in the 201 
coffee group for mean salivary caffeine concentration (independent samples t test, p=0.202). 202 
In the control group, all samples were less than 1 µM. Based on returned coffee portions, the 203 
median daily coffee intake was 3.9 servings (range: 3.5 – 4.3 servings/day). 204 
Genotyping 205 
The distribution of genotypes was as expected within the population and did not deviate from 206 
the Hardy-Weinberg equilibrium (Pearson χ2 test with 1 df, p>0.05). There were two 207 
participants with the CC genotype, both of which had been randomized to the control group, 208 
resulting in a bias between coffee and control groups for this genotype. Whilst one C allele is 209 
deemed sufficient to confer a “slow” caffeine metaboliser phenotype and two A alleles are 210 
required for a “fast” caffeine metaboliser phenotype (29), a decision was made to exclude the 211 
two participants with the CC genotype prior to analyses to reduce the risk of bias when 212 
comparing groups.  213 
It is considered that the “fast” metaboliser phenotype requires induction by, for example, 214 
smoking (30,31) or heavy coffee consumption (32). Several dietary components have also been 215 
demonstrated to affect CYP1A2 activity; five portions per day of brassica vegetables have been 216 
reported to increase CYP1A2 activity, whilst five daily portions of apiaceous vegetables 217 
decrease activity (33). All participants were non-smokers and non-coffee drinkers when 218 
recruited, with a low intake of dietary inducers (mean daily intake: 0.25 portions) and inhibitors 219 
(mean daily intake: 0.26 portions).  Those with the AA genotype were therefore unlikely to 220 
have the “fast” metaboliser phenotype induced at the outset of the study. Nevertheless, for 221 
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clarity within the manuscript and in order to easily distinguish between the groups, those with 222 
the AA genotype will be reported as being “fast” metabolisers and those with the AC genotype 223 
as being “slow” metabolisers. The difference in the ratio of “fast” to “slow” metabolisers 224 
between groups was not statistically significant (Fisher’s Exact, p=0.678). 225 
Primary analysis: comparison of coffee (n=19) and control (n=8) groups 226 
Baseline measures: 227 
There were no differences at baseline between coffee and control groups for any of the 228 
anthropometric measures (age, weight, body fat, BMI, systolic and diastolic blood pressure, 229 
p>0.05). There were no differences between coffee and control groups pre-intervention for any 230 
of the single blood measures (fasted glucose, insulin, TAG, NEFA, TNF-, IL-6, Matsuda 231 
Index, total cholesterol  and HDL cholesterol, p>0.05). Nor were there any pre-intervention 232 
differences between groups for postprandial glucose, insulin, TAG and NEFA time-point data 233 
(p>0.05).  234 
Effect of intervention: 235 
There were no significant differences between coffee and control groups, post-intervention, for 236 
change in: fasted blood measures, Matsuda Index and anthropometric measures (p>0.05). Nor 237 
were there any significant differences between groups in their response to the intervention for 238 
the postprandial glucose, insulin, TAG and NEFA time-point data (p>0.05). However, a strong 239 
trend for a treatment * time * visit interaction was observed for the postprandial insulin time-240 
point data, following the intervention (repeated measures (six time-points) full factorial fixed 241 
effects (treatment, visit, time) linear model, p=0.054). Examination of the mean postprandial 242 
insulin responses for each group revealed a delayed postprandial insulin peak post-intervention 243 
for the coffee group only (Figure 2). 244 
 245 
Secondary analysis: comparison of rs762551 genotypes 246 
Baseline measures (Coffee and control groups combined: AC genotype, n=14; AA 247 
genotype, n=13): 248 
There were no significant differences between genotypes at baseline for any of the 249 
anthropometric measures (p>0.05). Nor were there any differences between genotypes for 250 
fasted or postprandial insulin and TAG, Matsuda Index, total and HDL cholesterol, IL-6 and 251 
TNF- (p>0.05). 252 
There were no significant differences between genotypes at baseline for either fasted glucose 253 
or the postprandial glucose response (p>0.05). However, when gender was added as a cofactor 254 
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to genotype in the analysis, an effect of genotype was observed for fasted glucose (two-way 255 
ANOVA with interaction effect, p=0.014) and postprandial glucose time-point data (repeated 256 
measures (six time-points) full factorial fixed effects (genotype, gender, time) linear model, 257 
p=0.017), with the AA genotype (“fast” metaboliser phenotype) exhibiting a smaller overall 258 
postprandial glucose excursion at baseline. There was a trend for a difference in fasted NEFA 259 
between the AA and AC genotypes (independent samples t test, p=0.062). When gender was 260 
added to the baseline analysis as a cofactor, the previously observed trend for a difference in 261 
fasted NEFA between genotypes became significant (two-way ANOVA with interaction effect, 262 
p=0.036) and a strong trend for an effect of genotype was observed in the postprandial time-263 
point data (repeated measures (six time-points) full factorial fixed effects (genotype, gender, 264 
time) linear model, p=0.055), with the AC genotype (“slow” metabolisers) displaying higher 265 
fasted and postprandial NEFA at baseline. 266 
Effect of genotype on participants’ response to the intervention within the coffee group 267 
(AC genotype, n=9; AA genotype, n=10)  268 
There were no significant differences between rs762551 genotypes in the coffee group in their 269 
response to the intervention for any anthropometric measure (p>0.05).  270 
A visit * genotype effect (repeated measures (six time-points) full factorial fixed effects 271 
(genotype, visit, time) linear model, p=0.048) was observed when the glucose time-point data 272 
were analysed, with an increase in postprandial glucose response being observed in the AA 273 
genotype and a decrease observed in the AC genotype (“slow” metaboliser phenotype) 274 
following the coffee intervention (Figure 3).  275 
There were no differences between genotypes for serum insulin (p>0.05). Both genotypes 276 
displayed a delayed peak following the intervention (not shown) as was observed in the coffee 277 
group in the primary analysis. 278 
A visit * genotype * time interaction was found for the postprandial NEFA response (repeated 279 
measures (six time-points) full factorial fixed effects (genotype, visit, time) linear model, 280 
p=0.044) with greater NEFA suppression being observed in the AA genotype (“fast” 281 
metabolisers) following the intervention and an apparent reduction in NEFA suppression 282 
observed in the AC genotype (Figure 4).  283 
There were no differences between genotypes in their response to the intervention for change 284 
in Matsuda Index, total and HDL cholesterol, IL-6 and TNF- (p>0.05). 285 
  286 
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Discussion 287 
This is the first study to examine the longer-term effects of coffee drinking in coffee-naïve 288 
individuals with normal glucose metabolism. Furthermore, this is the first report that these 289 
effects may be modulated by the rs762551 SNP. The results of the primary analysis suggest 290 
that daily, moderate consumption of instant coffee (4 cups/day) does not affect the postprandial 291 
glucose and lipid response in healthy adults, but may result in a delayed postprandial insulin 292 
peak. This delayed insulin peak is comparable to the reduced first-phase insulin response 293 
documented in T2D, however, unlike in T2D (34), there was no consequent deterioration in 294 
glycaemia at this time, so the physiological significance is unclear. It is possible that this result 295 
is indicative of enhanced insulin sensitivity, as has been demonstrated following longer term 296 
caffeine consumption in animal models (35), however there was no observed effect on the 297 
Matsuda Index, a measure of postprandial insulin sensitivity. The lack of effect of coffee on 298 
postprandial glucose is consistent with studies in habitual coffee drinkers (10,12), but in contrast 299 
to Ohnaka et al. who observed a reduction in the postprandial glucose response in coffee-naïve 300 
individuals following 16 weeks of coffee intake (13). Whilst coffee dose (6-8 g instant granules 301 
per day) and compliance, as estimated from random saliva samples, were similar between 302 
studies, the study populations were quite different. Ohnaka et al. studied overweight, older men 303 
with IFG, whereas the participants in this study were mostly normal weight and younger with 304 
fasted glucose within the normal range. Impaired fasting glucose is characterised not only by 305 
elevated fasting glucose, but also by decreased β cell glucose sensitivity and reduced first phase 306 
insulin response leading to an elevated glycaemic response in comparison with subjects with 307 
normal glucose tolerance (36).  It is likely that any effects in a healthy population would be of a 308 
smaller magnitude and a larger sample size may be required for any observed effects to reach 309 
statistical significance.  310 
The coffee used in this study, a commercially available instant coffee sold in the UK, was 311 
relatively low in caffeine (2.2 g/100 g) and CGAs (2.2 g/100 g) in comparison with some other 312 
instant coffees, with reported caffeine ranges of 2.5 – 5.0 g/100 g (37) and CGA ranges of 2.1 – 313 
4.3 g/100 g (19). As Ohnaka et al. did not report a coffee analysis for comparison, it is not 314 
possible to examine whether a difference in coffee composition between the two studies could 315 
contribute to the different outcomes.  316 
Participants in the coffee group abstained from coffee drinking for two days prior to their 317 
follow-up visit to ensure that chronic rather than acute effects were examined. This may, 318 
however, have reduced any effects of the intervention as it is unknown how long it takes for 319 
chronic effects of coffee drinking to dissipate. Unlike the present study, participants in Ohnaka 320 
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et al.’s study were required to fast from 9pm the evening before their study day with no 321 
requirement to abstain from coffee for a longer period. The mean plasma t1/2 of caffeine is 5 h, 322 
although this can vary considerably between individuals, with most caffeine being cleared 323 
within 4-5 half-lives (approximately 24 h) (38). Whilst chlorogenic acids are extensively 324 
metabolised, several of their metabolites, such as dihydroferulic acid-4-O-sulfate and ferulic 325 
acid-4-O-sulfate, have half-lives in excess of 4 h (39). It is likely therefore that the participants 326 
in Ohnaka et al.’s study were not entirely free of either caffeine or chlorogenic acid metabolites 327 
on the study days, which may contribute to the difference in results between studies. 328 
Two meta-analyses have concluded that longer-term coffee consumption results in raised total 329 
and LDL cholesterol and TAG, with no effect on HDL cholesterol (40,41). They observed that 330 
most of the effect came from studies using boiled coffee which contains relatively large 331 
amounts of the  diterpenes, cafestol and kahweol, which are known to be lipid raising (42,43). 332 
Whilst the diterpene content wasn’t measured in the current study, instant coffee has been 333 
demonstrated to be relatively low in these compounds, as most of the diterpene content is lost 334 
during the production process (44). This may explain the lack of observed effect of instant coffee 335 
on total cholesterol and TAG in the current study. 336 
Finally, it should be noted that the participants in the current study may not be representative 337 
of the general population in some respects as it is possibly rare to find coffee-naïve individuals 338 
willing to drink coffee for the purposes of a research project. However, participants were 339 
randomly allocated to coffee or control group, minimising the risk of bias between groups.  340 
Little is known regarding mechanisms for the apparent protective effect of chronic coffee 341 
consumption suggested by the epidemiology. In fact, it would appear that caffeine may have a 342 
detrimental effect on glucose metabolism as caffeine and caffeinated coffee, have both been 343 
documented to increase the acute postprandial glucose response more than a control (7,8,45) 344 
whereas decaffeinated coffee frequently has no effect (46). Caffeine acutely raises plasma 345 
glucose concentrations by a variety of mechanisms; it raises plasma adrenalin and is also a non-346 
specific adenosine receptor antagonist, both of which actions lead to a decrease in glucose 347 
disposal rates (47). In contrast, large doses (1g) of CGAs have been observed to reduce the 348 
postprandial glucose response (48), with suggested mechanisms including inhibition of glucose 349 
absorption in the gut (49) and inhibition of hepatic glucose output (50).  350 
Whilst a single cup of instant coffee does not contain high amounts of caffeine or CGAs, a 351 
heavy coffee drinker may consume a considerable amount over the course of a day, particularly 352 
if also consuming espresso-type coffees which can contain up to 422 mg total CGAs and 322 353 
mg caffeine in a single serving (20). Frequent coffee intake may therefore result in sufficiently 354 
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high concentrations of CGA in the blood to result in a reduced postprandial glycaemic response 355 
as observed with a single high dose (48).  356 
It should also be considered that coffee may exert protective effects in ways not directly related 357 
to postprandial glycaemia or lipaemia. One potential mechanism may be by inhibiting the 358 
formation of amyloid fibrils from human islet amyloid polypeptide (hIAPP). These fibrils 359 
accumulate in the pancreas and are prevalent in T2DM (51). Chlorogenic acids and their 360 
metabolites have been demonstrated to suppress formation of these amyloids in vitro, although 361 
it should be noted that the authors reported non-physiological doses were used in that study (52). 362 
Secondary analysis 363 
There was significant individual variation in response to the coffee intake, which may be 364 
partially explained by the results of the secondary analysis. The baseline differences in NEFA 365 
and glucose between rs762551 genotypes was unexpected and may be indicative of a “less 366 
healthy” overall physiological state in those with the AC genotype, as reduced NEFA 367 
suppression and elevated postprandial glucose response may be a result of reduced insulin 368 
sensitivity, a key risk factor for development of T2DM. This is consistent with the 369 
epidemiology observing an association between carriers of the “slow” C allele and increased 370 
T2D risk, irrespective of coffee consumption (53). The participants reported to be non-smokers 371 
and non-coffee drinkers and were therefore unlikely to have the “fast” metaboliser phenotype 372 
induced at baseline. Furthermore, intake of dietary inducers and inhibitors was low, with no 373 
differences between genotypes (p>0.05). The data therefore imply that there is some as yet 374 
uncharacterized effect of this SNP, independent from its effects on caffeine 375 
metabolism/CYP1A2 activity, which has resulted in the baseline differences. This warrants 376 
further investigation. 377 
The increased postprandial glucose following the coffee intervention in those with the AA 378 
(“fast”) genotype suggests that there could be a potentially detrimental effect of habitual coffee 379 
drinking on glycaemia in this group. It is unknown whether this is physiologically relevant as 380 
the observed increase in glucose response was not pathologically high and glucose levels at 2 h 381 
were normalized, however there is increasing interest currently in the long-term effects of 382 
changes to postprandial glucose and its role as a risk factor in the progression towards 383 
metabolic diseases such as T2D. In apparent contrast to this however, the coffee intervention 384 
resulted in enhanced NEFA suppression in the AA genotype, suggesting a potentially beneficial 385 
effect of coffee on adipose tissue insulin sensitivity.  386 
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Conversely, the impaired NEFA suppression in the AC (“slow”) genotype following the 387 
intervention is particularly interesting when one considers that this group also exhibited higher 388 
NEFA concentrations pre-intervention than the AA (“fast”) genotype.  389 
Several other SNPs on the CYP1A2 gene are associated with decreased enzyme activity. The 390 
rs2069514 SNP in particular may be a confounder as a cross-sectional study in Japanese men 391 
found this SNP modified the association between coffee drinking and prevalence of T2D (54). 392 
The A allele, which results in decreased enzyme activity, is uncommon in Caucasians (8%), 393 
but is relatively common in Asians (28%). As 8/19 of the coffee group were Asian it is likely 394 
that some participants were also carriers of this allele.  395 
In conclusion, the primary analysis found no effects of moderate consumption of instant coffee 396 
on markers of glucose and lipid metabolism in healthy adults. However the secondary analysis 397 
revealed baseline differences between genotypes in the coffee group suggesting that coffee-398 
naïve individuals who are carriers of the “slow” C allele may exhibit an impaired glucose and 399 
lipid profile, demonstrated by a greater postprandial glucose response and reduced postprandial 400 
NEFA suppression, relative to those homozygous for the “fast” A allele. Furthermore, the 401 
differences observed between the two genotypes in their response to the intervention, suggest 402 
a potentially detrimental effect of coffee on glucose response in the AA (“fast”) genotype and 403 
on NEFA response in the AC (“slow”) genotype. These contrasting results between genotypes 404 
may explain the lack of overall effect from coffee in this study, particularly as the coffee group 405 
had an even distribution of genotypes (AA, n=10; AC, n=9). This novel finding may also 406 
partially explain the inconsistency in the epidemiology regarding coffee consumption and T2D 407 
risk as, to date, these studies have not genotyped their participants for this confounder. 408 
These differences between genotypes make it inadvisable at this stage to recommend either 409 
coffee drinking or abstention to either group although such data may be combined with other 410 
“personalized nutrition approaches”.  Despite the small sample size of the current study, a 411 
clear interaction between coffee intake and the rs762551 SNP was observed. A larger study 412 
with additional health outcomes is needed to confirm these findings and to further investigate 413 
the potential impact of this SNP.  414 
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Figure 1. Study timeline. Following a two day coffee pre-trial and two week caffeine washout 
period, participants attended their first study visit where baseline measures were taken. 
Following this, they were notified of their randomly allocated group (either coffee or control). 
The coffee group then consumed four cups/day of instant coffee for 12 weeks, whereas the 
control group remained caffeine free. After a final caffeine washout period (2 days), all 
participants returned for their second study visit. *Blood samples were taken at 0, 15, 30, 60, 90 
and 120 min. 
Figure 2. Postprandial insulin response by visit and treatment group. All measures were taken in 
a caffeine-free state. A liquid meal was consumed immediately after the fasted blood sample was 
taken. The meal start time was recorded and all subsequent blood samples were timed from this 
point. Panel A: coffee group (n=19). Panel B: control group (n=8). There was no overall 
difference in the postprandial response between groups (repeated measures (six time-points) full 
factorial fixed effects (treatment, visit, time) linear model, p>0.05), but there was a trend for a 
visit * time * treatment interaction (p=0.054), with the coffee group displaying a later peak at the 
second visit. Error bars are SEM.  
     Coffee group, pre-intervention.        Coffee group post-intervention.       Control group pre-
intervention.         Control group, post-intervention. 
 Figure 3. Postprandial glucose response by visit and genotype within the coffee group. All 
measures were taken in a caffeine-free state. A liquid meal was consumed immediately after the 
fasted blood sample was taken. The meal start time was recorded and all subsequent blood 
samples were timed from this point. Panel A: AC genotype (“slow” caffeine metabolisers, n=9). 
Panel B: AA genotype (“fast” caffeine metabolisers, n=10). The two genotypes responded 
differently to the coffee intervention (repeated measures (six time-points) full factorial fixed 
effects (genotype, visit, time) linear model, visit * genotype interaction, p=0.048). Error bars are 
SEM. 
     AC genotype, pre-intervention.        AC genotype post-intervention.       AA genotype pre-
intervention.          AA genotype, post-intervention. 
Figure 4. Postprandial NEFA response by visit and genotype within the coffee group (AA 
genotype, n=10; AC genotype, n=9). All measures were taken in a caffeine-free state. A liquid 
meal was consumed immediately after the fasted blood sample was taken. The meal start time 
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was recorded and all subsequent blood samples were timed from this point. The two genotypes 
responded differently to the coffee intervention (repeated measures (six time-points) full factorial 
fixed effects (genotype, visit, time) linear model, visit * time * genotype interaction, p=0.044). 
Error bars are SEM. 
     AC genotype, pre-intervention.        AC genotype post-intervention.       AA genotype pre-
intervention.          AA genotype, post-intervention. 
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Table 1: Baseline participant characteristics 
There were no statistically significant differences between coffee and control groups at baseline (1Mann-Whitney U test, p>0.05; 
2independent samples t test, p>0.05). BMI, body mass index; CHOL, total cholesterol; DBP, diastolic blood pressure; HDL, high 
density lipoprotein cholesterol; NEFA, non-esterified fatty acids; SBP, systolic blood pressure; TAG, triacylglycerol. 
  
  Coffee group   Control group 
 Female (n=9)  Male (n=10)  All (n=19)  Female (n=4)  Male (n=4)  All (n=8) 
 Median Range  Median Range  Median Range  Median Range  Median Range  Median Range 
1Age, y 21 19-26  23.5 18-42  22 18-42  24.5 21-33  22.5 19-41  23.5 19-41 
1HDL, mmol/L 1.24 
0.99-
1.67  1.12 
1.03-
1.64  1.14 
0.99-
1.67  1.60 
1.20-
1.66  1.25 
0.83-
1.64  1.41 
0.83-
1.67 
 Mean SD  Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
2Height, m 1.64 0.05  1.74 0.09  1.69 0.09  1.70 0.10  1.64 0.09  1.67 0.09 
2Weight, kg 58.7 8.0  74.7 11.6  67.1 12.8  67.8 19.7  61.2 9.6  64.5 14.7 
2SBP, mm Hg 114 6.3  125 9.6  120 9.9  117 11.7  116 7.3  117 9.0 
2DBP, mm Hg 72 4.5  73 7.8  72 6.3  74 12.4  70 8.2  72 9.9 
2BMI, kg/m2 21.8 2.2  24.8 3.1  23.4 3.0  23.0 4.0  22.8 2.7  22.9 3.1 
2Body fat, % 25.3 6.6   18.1 7.5   21.5 7.8   29.1 10.3   13.8 4.5   21.5 11.0 
2Glucose, 
mmol/L 4.46 0.53  4.77 0.28  4.62 0.44  4.43 0.31  4.73 0.32  4.58 0.33 
2Insulin, pmol/L 64.9 24.0  69.1 23.8  67.1 23.4  55.8 12.1  54.9 12.7  55.4 11.5 
2TAG, mmol/L 0.88 0.34  1.08 0.37  0.98 0.36  0.92 0.18  0.98 0.63  0.95 0.43 
2NEFA, mmol/L 0.53 0.24  0.65 0.29  0.60 0.27  0.65 0.24  0.55 0.18  0.60 0.20 
2CHOL, mmol/L 4.21 0.71  4.03 0.64  4.11 0.66  4.19 0.45  4.05 0.50  4.12 0.45 
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Table 2: Instant coffee analysis: caffeine, trigonelline and key chlorogenic acids 
Compound (%) 
Amount per 
portion (mg) 
Caffeine  2.19 43.8 
Trigonelline 0.73 14.5 
3-CQA 0.55 10.9 
4-CQA 0.68 13.5 
5-CQA 0.85 16.9 
3,4-diCQA 0.04 0.8 
3,5-diCQA 0.05 1.0 
4,5-diCQA 0.03 0.6 
Chlorogenic Acid (Total) 2.18 43.6 
CQA, caffeoylquinic acid. 
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   Other reasons (n=0) 
Analysed  (n=8) 
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